Irradiation of HPV-associated oropharyngeal cancer: Is less really more?

Mallory, Matthew; Butler-Xu, Y.S.; Chen, Allen M.

doi:10.18632/oncotarget.23769

Cited by 1 publication

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The other de-intensification treatment strategy currently subject to clinical research is overall radiation dose reduction (Table 3) (ref. 6,12,13 ).…”

Section: Reduction Of Total Radiation Dosementioning

confidence: 99%

“…There is global consensus about the need for treatment de-escalation (reduction of toxicity while preserving antitumour efficacy) for patients with HPV+OPC (ref. 12,13 ). Since surgery coupled with concomitant chemoradiation (CRT) is the cornerstone of a curative treatment in head and neck cancers, the current clinical studies focus primarily on minimally-invasive surgical procedures, administered radiation dose reduction, and nephrotoxic cisplatin dose substitution/reduction.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Has the time come for de-escalation in the management of oropharyngeal carcinoma?

Durkova¹,

Boldis²,

Kovacova

2019

BIOMED PAP

View full text Add to dashboard Cite

Over the course of the last two decades, there has been a decrease in the incidence of head and neck cancers thanks to a decreasing prevalence of smoking. However, a new risk factor has been coming to the fore: human papillomavirus infection (HPV). HPV-positive oropharyngeal squamous cell carcinoma (HPV+OPC) is more sensitive to chemotherapy and radiotherapy, which translates to a much better prognosis with conventional treatment protocols than tumours that are HPV-negative. Traditional therapeutic interventions are associated with substantial morbidity and have a great impact on patient quality of life. The main focus is on identifying an ideal group of HPV-positive patients who could receive de-intensification treatment regimens aimed at avoiding the late toxicity of treatment. Various strategies are considered, such as reduction in radiotherapy dose following induction chemotherapy, radiotherapy alone, minimally invasive surgical techniques, and substituting platinum-based chemotherapy. The first generation of de-escalation randomised phase III trials have now been published. The following review summarizes the current knowledge and treatment of oropharyngeal carcinoma.

show abstract

“…The other de-intensification treatment strategy currently subject to clinical research is overall radiation dose reduction (Table 3) (ref. 6,12,13 ).…”

Section: Reduction Of Total Radiation Dosementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%